Alumis Inc. · NASDAQ:ALMS
Alumis — Merger or Acquisition (February 2025)
18 slides from Alumis's merger presentation, Feb 6, 2025
Slide 1: Alumis and ACELYRIN Merger Investor Presentation
| Alumis and ACELYRIN Merger Investor Presentation February 6, 2025 Transform Therapies. Reimagine Lives.
Slide 2: Disclaimer
Disclaimer Financial Disclaimer Alumis' and ACELYRIN's audited consolidated financial statements for the year ended December 31, 2024 are not yet available. Accordingly, the information presented herein regarding cash, cash equivalents and marketable securities as of December 31, 2024, reflects each
Slide 3: Creating Well Capitalized Company with Multiple Upcoming Expected Development Milestones
Creating Well Capitalized Company with Multiple Upcoming Expected Development Milestones and Extended Runway into 2027 〉 Creates a late-stage clinical biopharma company dedicated to innovating, developing and commercializing transformative therapies for immune-mediated diseases 〉 Differentiated pipe
Slide 4: Transaction Highlights
Transaction Highlights 〉 All stock merger Consideration 〉 ACELYRIN stockholders to receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock owned Pro Forma 〉 Alumis stockholders to own ~55% of the combined company Ownership1 〉 ACELYRIN stockholders to own ~45% of the comb
Slide 5: Late-Stage Pipeline With Multiple Near-Term Catalysts
Late-Stage Pipeline With Multiple Near-Term Catalysts DEVELOPMENT ANTICIPATED TARGET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MILESTONES Moderate-to-Severe 1H 2026: Phase 3 topline Plaque Psoriasis (PsO) data ESK-001 Systemic Lupus 2026: Phase 2b topline data (TYK2) Erythematosus (SLE) Add’l indications
Slide 6: Alumis Pipeline: Development Plan is on Track
Alumis Pipeline: Development Plan is on Track A-005 Ongoing Phase 3 trials of Ongoing Phase 2b trial of Phase 2 trial of A-005 in ESK-001 in moderate-to- ESK-001 in systemic lupus multiple sclerosis severe plaque psoriasis erythematosus Topline data readout Topline data readout Initiation expected i
Slide 7: ACELYRIN's Lonigutamab
ACELYRIN’s Lonigutamab A Next-Generation Subcutaneous Anti-IGF-1R Therapy With Best-in-Class Potential in TED Evaluating Lonigutamab Development Plan 〉 Lonigutamab is a unique asset given its mechanism of action and has best-in- class potential 〉 ACELYRIN plans to re-evaluate the development program
Slide 8: Flexibility and Runway to Advance Late-stage Therapies
Flexibility and Runway to Advance Late-stage Therapies 〉Standalone: Alumis and ACELYRIN had cash, cash equivalents and marketable securities of ~$289 million and ~$448 million, respectively, on a preliminary basis, as of December 31, 2024 〉Combined Company: Pro forma cash of ~$737 million as of Dece
Slide 9: Recent Achievements and Anticipated Multiple Near-Term Milestones
Recent Achievements and Anticipated Multiple Near-Term Milestones 2024 2025 2026 MAR24 ESK-001 – Present Phase 2 1Q25 ESK-001 – PsO Phase 2 1H26 ESK-001 – PsO Phase 3 Topline Data STRIDE and OLE Data at AAD ✓ OLE Data Update 2026 ESK-001 – SLE Phase 2b Topline Data APR24 A-005 – Phase 1 Initiation ✓
Slide 10: Alumis/ACELYRIN Combination
Alumis/ACELYRIN Combination Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases Strong Portfolio, Large Opportunity 〉 Three potential best-in-class molecules: two advanced clinical TYK2 inhibitors and an
Slide 11: Thank You!
Thank You! 7 alumis
Slide 12: Appendix
Appendix 7 alumis
Slide 13: Alumis: A Well Characterized Late-Stage Portfolio with Significant Opportunity
Alumis: A Well Characterized Late-Stage Portfolio with Significant Opportunity Large Two highly differentiated advanced clinical TYK2 inhibitors provide strategic opportunities Opportunity across a broad range of immune mediated diseases Genomic, proteomic and clinical insights validate and drive ou
Slide 14: TYK2 Is One Of The Most Attractive Targets In I&I
TYK2 Is One Of The Most Attractive Targets In I&I IL-23, … IL-12, IFN 〉 TYK2 pathway drives immune mediated diseases TYK2 in the periphery and CNS via IL23, IL17 and IFN STAT 〉 TYK2 inhibition interrupts the self-fueling inflammatory cycle by stopping the release of NUCLEUS inflammatory mediators In
Slide 15: ESK-001 and A-005: A Highly Differentiated TYK2i Portfolio
ESK-001 and A-005: A Highly Differentiated TYK2i Portfolio ESK-001: next-generation TY2 inhibitor for immune-mediated diseases 〉 Maximal Target Inhibition Phase 3 dose fully inhibits TYK2 by every measure in skin and blood* 〉 High Response Oral Long term PASI and sPGA response rates competitive with
Slide 16: Maximal Target Inhibition Led to 15-20% Increase in Clinical Response (PASI)
Maximal Target Inhibition Led to 15-20% Increase in Clinical Response (PASI) Maximal Target Inhibition Maintained Across 24-hour Clinical Outcomes at 28 Weeks Dosing Period (Phase 1 multidose trough PK) (OLE Phase 2, PASI as observed) 1000 ESK-001 Mean Trough Concentration (ng/mL) 100 93 Patients wi
Slide 17: TYK2 Class has Extensive Validation with Substantial Market Potential
TYK2 Class has Extensive Validation with Substantial Market Potential Across Immune-Mediated Diseases Indication Market Size1 Clinical POC Ongoing Trial Genetic Evidence Biologic Rationale Plaque Psoriasis >$25B Psoriatic Arthritis >$9B Systemic Lupus >$4B Ulcerative Colitis >$9B Crohn’s Disease >$1
Slide 18: Lonigutamab – A Unique Mechanism for TED Patients
Lonigutamab – A Unique Mechanism for TED Patients 〉 Robust subcutaneous efficacy in TED Patients comparable to SoC and investigational anti-IGF-1R IV agents 〉 First clinical subcutaneous data in TED patients informs clinical development 〉 Optimized safety profile: potential for lower risks of hearin